Eli Lilly (LLY) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Eli Lilly (LLY) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 40.41%
Mar 31, 2024 -9.43%
Dec 31, 2023 258.44%
Sep 30, 2023 -24.80%
Jun 30, 2023 129.96%
Mar 31, 2023 93.02%
Dec 31, 2022 26.59%
Sep 30, 2022 21.18%
Jun 30, 2022 -1.13%
Mar 31, 2022 80.53%
Dec 31, 2021 17.47%
Sep 30, 2021 7.37%
Jun 30, 2021 13.21%
Mar 31, 2021 25.23%
Mar 31, 2019 38.28%
Dec 31, 2018 -65.13%
Sep 30, 2018 -45.87%
Jun 30, 2018 -15.14%
Mar 31, 2018 -49.63%
Dec 31, 2017 -31.24%